Is Broad-Based Genomic Sequencing Prognostic in NSCLC?

Genomic sequencing in the community oncology setting can be challenging. To determine the association between genomic sequencing and treatment or survival among patients with advanced non–small-cell lung cancer (NSCLC) in a community setting, investigators retrospectively reviewed data in the Flatiron Health Database from 2011 to 2016 on 5688 patients (80% were smokers) from 191 community practices with unresectable nonsquamous NSCLC who received at least one line of systemic therapy.

Of these patients, 15.4% received multigene panel sequencing, and 84.6% received only EGFR or ALK testing. Broad-based genomic sequencing evaluated more than 30 genes and was performed prior to third-line therapy, whereas the EGFR and ALK testing was performed …